# Tyra Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tyra-biosciences

- Industry: Biotechnology
- Headquarters: Carlsbad, US
- Website: www.tyra.bio
- Total disclosed funding: $156M
- Latest round: Series B (Mar 31, 2021)
- Investors on record: 9

## About

Based in California, US, and founded in 2018 by CEO and co-founder Daniel Bensen and Todd Harris. Tyra Biosciences, Inc. is a biotechnology company that develops therapeutics targeting drug-resistant cancer cells. In January 2020, the company received USD 50 million in Series A funding, followed by Series C funding in March 2021, from Nextech Invest, Cormorant Asset Management, BVF Partners, Janus Henderson Investors, Logos chipping, Alta Partners, RA Capital, Boxer Capital of Tavistock Group and Canaan.The shares began trading on the Nasdaq on September 15, 2021, under the ticker symbol TYRA. In February 2024, Tyra Biosciences, Inc. raised USD 200 million in PIPE funding led by  RA Capital Management, with participation from 5AM Ventures, BVF Partners, Boxer Capital, Nextech, and OrbiMed Advisors. Other unspecified investors also participated in the round. As part of the transaction, the company agreed to sell 15.4 million shares for USD 200 million at USD 13.01 per share.

Tyra Biosciences, Inc. offers medicines that work as inhibitors that re-sensitize cancer cells to platinum-based chemotherapy by targeting a newly identified protein, allowing patients to pursue inhibitors for malignancies that have gained resistant mutations while on previous treatments. The company offers cancer drugs that target new pathways of cancer therapies that have acquired resistance in oncology to produce drugs with a purpose for the benefit of patients.

Tyra Biosciences, Inc. plans to use the February 2024 funding to accelerate and expand its in-house drug discovery platform, SNAP, and to advance its pipeline of novel, small molecule therapies into the clinic.

## Funding rounds

- Series B, Mar 31, 2021, $106M — Alta Partners, Canaan Partners, Nextech, BVF Partners, RA Capital Management, Cormorant Asset Management, Boxer Capital, Janus Henderson Investors, Logos Capital
- Series A, Jan 10, 2020, $50M — Alta Partners, Canaan Partners, RA Capital Management, Boxer Capital

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A, Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Janus Henderson Investors — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B